IL1B and neoplasm: MDSCs inhibit anti-cancer immune responses by releasing cytokines (IL-1 and TGF-β), ROS, and reactive nitrogen species (RNS) that condition the tumor microenvironment and by stimulating Foxp3+ Treg cells and M2 tumor-associated macrophages (TAM) [171].